MCL-1 can be considered an intrinsic as well as an acquired resistance factor that limits the efficacy of navitoclax, ABT-737 and venetoclax.24, 25, 26, 27, 28 However, MCL-1 protein expression does not directly correlate with the sensitivity of NHL cell lines to navitoclax or venetoclax (Figure 1b and Supplementary Figure 2). The gene discussed is MCL1; the disease is non-Hodgkin lymphoma.